Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/33614
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-06-21
Colecciones
- INI - Artigos de Periódicos [3398]
Metadatos
Mostrar el registro completo del ítem
HUMAN T-LYMPHOTROPIC VIRUS TYPE II AND NEUROLOGICAL DISEASE
Afiliación
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / University College Dublin. Conway Institute of Biomolecular and Biomedical Research. Department of Medical Microbiology. Dublin, Ireland.
University College Dublin. Conway Institute of Biomolecular and Biomedical Research. Department of Medical Microbiology. Dublin, Ireland.
University College Dublin. Conway Institute of Biomolecular and Biomedical Research. Department of Medical Microbiology. Dublin, Ireland.
Resumen en ingles
Human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II) are closely related retroviruses with similar bio-logical properties and common modes of transmission. HTLV-I infection is endemic in well-defined geographic regions,and it is estimated that some 20 million individuals are infected worldwide. Although most infected individuals areasymptomatic carriers, some 2 to 5% will develop a chronic encephalomyelopathy, HTLV-I–associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast with HTLV-I, the role of HTLV-II in the development of neuro-logical disorders is much less clear. HTLV-II is endemic in many native Amerindian groups and epidemic in injectingdrug users (IDUs) worldwide. To evaluate the role of HTLV-II in neurological disease, we have critically reviewed allreported cases of HTLV-II–associated disorders. This has confirmed that although rare infection is associated with adisorder clinically similar or identical to HAM/TSP. However, most reports that have attributed infection to a range ofother neurological disorders are difficult to evaluate in that in many cases either the association appears to be fortuitousor the presentations were confounded by a background of concomitant human immunodeficiency virus–1 infectionand/or active IDU. In view of the many HTLV-II–infected individuals in urban areas of North America and Europe,neurologists should be aware of the potential clinical consequences of this infection.
Compartir